Rotavirus Vaccine to Overcome Resistance to Cancer Immunotherapy

The American Association for Cancer Research Annual Meeting 2018featured a study suggesting that rotavirus vaccine may overcome cancer cells' resistance to new-generation immunotherapies called immune checkpoint inhibitors.
Immune checkpoint inhibitor immunotherapiesare medicines capable of removing the immune system's blindness to cancer cells. They are among the leading new cancer treatments, effective to varying degrees in many cancers and particularly in some types. Until as recently as 2012, cancer treatment meant only cancer surgery, chemotherapy, radiotherapy, interventional radiology procedures, molecular treatments and targeted smart drugs , whereas immunotherapies have now joined this list. To date, immunotherapies have received FDA approval for malignant melanoma, a skin cancer, non-small cell lung cancer, Hodgkin lymphoma, bladder cancer, head and neck cancers, Merkel cell skin cancer, colorectal cancers, stomach cancer and liver cancer. They have also been approved regardless of organ for advanced microsatellite instability-high (MSI-H) cancers.
Immunotherapies have certainly strengthened our options as a new cancer treatment, but they are not miracle drugs. Even in approved cancer types, high objective response rates are not achieved in every patient, or cancer cells may develop, over time, resistance to immunotherapy. Therefore, many studies are investigating ways to overcome mechanisms of immunotherapy resistance.
Pattern recognition receptors (PRRs)are considered a potential tool for increasing cancer cells' immunogenicity (recognizability by the immune system) and overcoming treatment resistance. In the study discussed here, researchers infected various cancer cell lines with rotavirus vaccine to stimulate pattern recognition receptors .
The study found that rotavirus vaccine not only stimulated pattern recognition receptors but also showed oncolytic properties. Therapeutic cancer vaccinessometimes use viruses. The viruses used to develop these vaccines are called oncolytic viruses . Oncolytic means "tumor-destroying."
Rotavirus vaccine triggered immunogenic cell death in cancer cell lines without adverse effects on healthy fibroblasts. This laboratory study was also adapted to mice, and intratumoral injection of the rotavirus vaccine showed an immune-mediated antitumor effect.
In neuroblastoma and lymphoma mouse models, intratumoral rotavirus vaccine therapy was shown to overcome resistance particularly to anti-CTLA-4 immune checkpoint inhibitors such as ipilimumab (Yervoy). After this experimental cancer vaccine, within the tumor microenvironmentan increase in activated T cells was observed.
Researchers concluded that intratumoral injection strategies using attenuated rotavirus vaccine could be rapidly translated into clinical use, including pediatric (childhood) cancers. Its oncolytic and immune-stimulating properties may offer a suitable strategy to overcome resistance to anti-PD-1 / anti-CTLA-4 treatment in cancer patients. Immunotherapy and other oncolytic virus vaccines are also being investigated; we will follow the clinical studies and share the results with you.
Sources
Immunostimulatory and oncolytic properties of rotavirus can overcome resistance to immune checkpoint blockade therapy.
Oral presentation at: 2018 American Association for Cancer Research Annual Meeting; April 14-18, 2018
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.